Tcr2 Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.48
- Today's High:
- $1.48
- Open Price:
- $1.48
- 52W Low:
- $0.821
- 52W High:
- $2.55
- Prev. Close:
- $1.48
- Volume:
- 0
Company Statistics
- Market Cap.:
- $58.11 million
- Book Value:
- 2.582
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -34.73%
- Return on Equity TTM:
- -91.46%
Company Profile
Tcr2 Therapeutics Inc had its IPO on 2019-02-14 under the ticker symbol TCRR.
The company operates in the Healthcare sector and Biotechnology industry. Tcr2 Therapeutics Inc has a staff strength of 58 employees.
Stock update
Shares of Tcr2 Therapeutics Inc opened at $1.48 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.48 - $1.48, and closed at $1.48.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Tcr2 Therapeutics Inc have slipped by -14.45%.
Tcr2 Therapeutics Inc's Key Ratios
Tcr2 Therapeutics Inc has a market cap of $58.11 million, indicating a price to book ratio of 0.222 and a price to sales ratio of 0.
In the last 12-months Tcr2 Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-128953000. The EBITDA ratio measures Tcr2 Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Tcr2 Therapeutics Inc’s operating margin was 0% while its return on assets stood at -34.73% with a return of equity of -91.46%.
In Q1, Tcr2 Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Tcr2 Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.2 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tcr2 Therapeutics Inc’s profitability.
Tcr2 Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.6323. Its price to sales ratio in the trailing 12-months stood at 0.
Tcr2 Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $151.51 million
- Total Liabilities
- $47.47 million
- Operating Cash Flow
- $21.69 million
- Capital Expenditure
- $158000
- Dividend Payout Ratio
- 0%
Tcr2 Therapeutics Inc ended 2024 with $151.51 million in total assets and $0 in total liabilities. Its intangible assets were valued at $151.51 million while shareholder equity stood at $101.33 million.
Tcr2 Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $47.47 million in other current liabilities, 4000.00 in common stock, $-541743000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.45 million and cash and short-term investments were $110.31 million. The company’s total short-term debt was $3,268,000 while long-term debt stood at $0.
Tcr2 Therapeutics Inc’s total current assets stands at $140.49 million while long-term investments were $0 and short-term investments were $95.86 million. Its net receivables were $0 compared to accounts payable of $6.32 million and inventory worth $0.
In 2024, Tcr2 Therapeutics Inc's operating cash flow was $21.69 million while its capital expenditure stood at $158000.
Comparatively, Tcr2 Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.48
- 52-Week High
- $2.55
- 52-Week Low
- $0.821
- Analyst Target Price
- $5.07
Tcr2 Therapeutics Inc stock is currently trading at $1.48 per share. It touched a 52-week high of $2.55 and a 52-week low of $2.55. Analysts tracking the stock have a 12-month average target price of $5.07.
Its 50-day moving average was $1.69 and 200-day moving average was $1.62 The short ratio stood at 1.29 indicating a short percent outstanding of 0%.
Around 149.5% of the company’s stock are held by insiders while 5431.5% are held by institutions.
Frequently Asked Questions About Tcr2 Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.